Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJID (2) Autor Pfaller,Michael A. (2) Sader,Helio S. (2) Barth,Afonso (1) Castanheira,Mariana (1) Flamm,Robert K. (1) Gales,Ana (1) Gales,Ana C. (1) Jones,Ronald N. (1) Mendes,Rodrigo E. (1) Shortridge,Dee (1) Zoccoli,Cássia (1) Mais... Palavra-chave Antimicrobial resistance (1) Ceftolozane-tazobactam (1) Drug resistance (1) Enterobacteriaceae (1) Latin America (1) Nosocomial infection (1) P. aeruginosa (1) SENTRY (1) Surveillance (1) Surveillance program (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2017 (1) 2001 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015) BJID Pfaller,Michael A.; Shortridge,Dee; Sader,Helio S.; Gales,Ana; Castanheira,Mariana; Flamm,Robert K.. ABSTRACT This study evaluated the in vitro activity of ceftolozane-tazobactam and comparator agents tested against Latin American isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients with health care-associated infections. Ceftolozane-tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor.A total of 2415 Gram-negative organisms (537 P. aeruginosa and 1878 Enterobacteriaceae) were consecutively collected in 12 medical centers located in four Latin American countries. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A10 document and the results interpreted according to EUCAST and CLSI breakpoint criteria. Results: Ceftolozane-tazobactam... Tipo: Info:eu-repo/semantics/article Palavras-chave: Ceftolozane-tazobactam; Drug resistance; Enterobacteriaceae; P. aeruginosa; Latin America; Surveillance. Ano: 2017 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702017000600627 Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY antimicrobial surveillance program BJID Sader,Helio S.; Gales,Ana C.; Pfaller,Michael A.; Mendes,Rodrigo E.; Zoccoli,Cássia; Barth,Afonso; Jones,Ronald N.. BACKGROUND: Pathogen frequency and resistance patterns may vary significantly from country to country and also in different hospitals within a country. Thus, regional surveillance programs are essential to guide empirical therapy and infection control measures. METHODS: Rank order of occurrence and antimicrobial susceptibility of pathogenic species causing bloodstream infections (BSI), lower respiratory tract infections (LRTI), wound or skin and soft tissue infections (WSSTI), and urinary tract infections (UTI) in hospitalized patients were determined by collecting consecutive isolates over a specified period of time, as part of the SENTRY Antimicrobial Resistance Surveillance Program (SENTRY). All isolates were tested by reference broth microdilution.... Tipo: Info:eu-repo/semantics/article Palavras-chave: SENTRY; Antimicrobial resistance; Nosocomial infection; Surveillance program. Ano: 2001 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702001000400006 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco